Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
Methods This prospective observatinal study included 128 HCV naive child A cirrhotic patients divided into two groups (77 patients were treated with SOF 400 mg, DACLA 60 mg and ribavirin 600 mg and 51 patients were treated with SOF 400 mg, LDV 90 mg and ribavirin 600 mg) for 12 weeks, during the tre...
Saved in:
| Main Authors: | Abbas Abbas, Amr Elsayed, Ehab M Abdelraheem, Hatem Hassan, Alshymaa Hassnine |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-12-01
|
| Series: | BMJ Open Gastroenterology |
| Online Access: | https://bmjopengastro.bmj.com/content/7/1/e000533.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COVID-19 in Cirrhotic Patients: Is Portal Vein Thrombosis a Potential Complication?
by: Alshymaa A Hassnine, et al.
Published: (2022-01-01) -
EFFECT OF ANTIVIRAL THERAPY ON CARDIOHEMODYNAMIC INDICATORS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS AND LIVER CIRRHOSIS
by: M. V. Chistyakova, et al.
Published: (2017-01-01) -
Prevalence and risk factors of liver fibrosis in patients with metabolic-associated fatty liver disease undergoing bariatric surgery
by: Amr Elsayed, et al.
Published: (2024-12-01) -
Hyperuricaemia and Gout: A Review
by: Amy Kopke, et al.
Published: (2010-04-01) -
Gut microbiome alterations and hepatic encephalopathy post-TIPS in liver cirrhosis patients
by: Shengpeng Li, et al.
Published: (2025-07-01)